JP2000510949A - 組織のリモデリングに関連した状態のための非観血的酵素スクリーン - Google Patents

組織のリモデリングに関連した状態のための非観血的酵素スクリーン

Info

Publication number
JP2000510949A
JP2000510949A JP09539033A JP53903397A JP2000510949A JP 2000510949 A JP2000510949 A JP 2000510949A JP 09539033 A JP09539033 A JP 09539033A JP 53903397 A JP53903397 A JP 53903397A JP 2000510949 A JP2000510949 A JP 2000510949A
Authority
JP
Japan
Prior art keywords
cancer
enzyme
subject
prostate
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP09539033A
Other languages
English (en)
Japanese (ja)
Inventor
マーシャ エイ． モーゼス
マイケル アール． フリーマン
ドゥミトリ ウィーダースチェイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24563830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2000510949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2000510949A publication Critical patent/JP2000510949A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP09539033A 1996-04-26 1997-04-25 組織のリモデリングに関連した状態のための非観血的酵素スクリーン Pending JP2000510949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63937396A 1996-04-26 1996-04-26
US08/639,373 1996-04-26
PCT/US1997/006909 WO1997041441A1 (en) 1996-04-26 1997-04-25 Non-invasive enzyme screen for tissue remodelling-associated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006119595A Division JP2006311860A (ja) 1996-04-26 2006-04-24 組織のリモデリングに関連した状態のための非観血的酵素スクリーン

Publications (1)

Publication Number Publication Date
JP2000510949A true JP2000510949A (ja) 2000-08-22

Family

ID=24563830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP09539033A Pending JP2000510949A (ja) 1996-04-26 1997-04-25 組織のリモデリングに関連した状態のための非観血的酵素スクリーン
JP2006119595A Ceased JP2006311860A (ja) 1996-04-26 2006-04-24 組織のリモデリングに関連した状態のための非観血的酵素スクリーン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006119595A Ceased JP2006311860A (ja) 1996-04-26 2006-04-24 組織のリモデリングに関連した状態のための非観血的酵素スクリーン

Country Status (6)

Country Link
US (1) US6037138A (enExample)
EP (3) EP0900381A1 (enExample)
JP (2) JP2000510949A (enExample)
AU (1) AU2681997A (enExample)
CA (1) CA2252648C (enExample)
WO (1) WO1997041441A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
GB9905817D0 (en) * 1999-03-12 1999-05-05 Oxford Glycosciences Uk Ltd Methods
CA2267481A1 (en) 1999-03-30 2000-09-30 Gabriel Pulido-Cejudo Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection
AU773329B2 (en) * 1999-05-14 2004-05-20 Proteomedica Ab Materials and methods relating to disease diagnosis
AU2001258929A1 (en) 2000-05-17 2001-11-26 Leids Universitair Medisch Centrum Proteolytic enzymes in urine as diagnostic parameters in diseases involving matrix remodelling
CA2425761C (en) * 2000-10-13 2005-11-15 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
EP1832876A3 (en) * 2000-10-13 2008-04-23 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
WO2003099107A2 (en) * 2002-05-22 2003-12-04 The Cleveland Clinic Foundation Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
AU2003297099A1 (en) * 2002-12-12 2004-06-30 Manoa Medical, Inc. Percutaneous removal of sentinel lymph node using contrast imaging for identification
US20080254490A1 (en) * 2005-02-02 2008-10-16 Ramkumar Menon Salivary Protease Assays for Identifying Increased Risk of Preterm Delivery Induced by Premature Rupture of Fetal Membranes
US20070196876A1 (en) * 2006-02-17 2007-08-23 Moses Marsha A Free NGAL as a biomarker for cancer
CN101680898A (zh) * 2007-05-10 2010-03-24 霍夫曼-拉罗奇有限公司 Timp-1作为结肠直肠癌标志的用途
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
US9804079B2 (en) 2012-04-19 2017-10-31 ProteinSimple Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US20150093757A1 (en) * 2013-09-27 2015-04-02 Protein Simple Methods. apparatus and systems for detection of total protein using capillary electrophoresis
IN202021002695A (enExample) 2020-01-21 2021-07-23

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) * 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5051361A (en) 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5340720A (en) * 1989-11-29 1994-08-23 University Of Kansas Methods of diagnosing and monitoring rheumatic diseases
AU647459B2 (en) * 1990-01-26 1994-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A method for quantitatively measuring collagenase
JP2503716B2 (ja) * 1990-04-06 1996-06-05 日東紡績株式会社 酸性ホスファタ―ゼ活性測定法
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
CA2139128A1 (en) * 1993-04-27 1994-11-10 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
WO1995015374A1 (en) * 1993-11-30 1995-06-08 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer

Also Published As

Publication number Publication date
US6037138A (en) 2000-03-14
CA2252648A1 (en) 1997-11-06
AU2681997A (en) 1997-11-19
EP1418434A3 (en) 2006-03-29
EP2060917A2 (en) 2009-05-20
EP2060917A3 (en) 2009-10-28
WO1997041441A1 (en) 1997-11-06
EP2060917B1 (en) 2014-01-01
CA2252648C (en) 2009-11-03
EP1418434A2 (en) 2004-05-12
JP2006311860A (ja) 2006-11-16
EP2060917B9 (en) 2014-06-04
EP0900381A1 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
US20150037814A1 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
US7153660B2 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
Armbruster Prostate-specific antigen: biochemistry, analytical methods, and clinical application
JP2000510949A (ja) 組織のリモデリングに関連した状態のための非観血的酵素スクリーン
US5902725A (en) Detection of prostate and other cancers by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
AU2002211697A1 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
Kozwich et al. Application of cancer procoagulant as an early detection tumor marker
US20040029200A1 (en) Method and kits for the detection of renal cell carcinoma in a biological fluid of a patient
AU775537B2 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
US20050130241A1 (en) Immunological detection of prostate diseases and prostasome-related conditions
AU757490B2 (en) Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
EP1832876A2 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060424